

A5 21. The solid lipid nanoparticles according to claim 2 [or 18], further comprising glycerol or fusogenic peptides.

A6 25. The solid lipid nanoparticles according to claim 2 [or 18], further comprising 1,2-dioleoyl-sn-3-phosphatidylethanolamine, diolein, fatty alcohol, cholesterol or bile salt.

A7 52. A complex of the emulsion according to [any of] claim[s] 1, [9 to 17] and a biologically active material selected from the group consisting of DNA, RNA, antisense nucleic acid, ribosome, polynucleotide, and oligonucleotide.

A8 54. The complex according to claim 52 [or 53], further comprising protamine sulfate, histone or cationic polymer.

A9 62. A complex of the solid lipid nanoparticles according to [any of] claim[s] 2, [12 to 19] with a biologically active material selected from the group consisting of DNA, RNA, antisense nucleic acid, ribosome, polynucleotide and oligonucleotide.

A10 64. The complex according to claim[s] 62 [or 63], further comprising protamine sulfate, histone or cationic polymer.

A11 69. The complex according to [any of] claim[s] 62 [to 68], further comprising lipophilic or amphiphilic drug in the fat, wherein the lipophilic or amphiphilic drug is selected from the group consisting of antivirals, steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, antibiotics, antifungals, vitamins, hormones, retinoic acid, prostaglandins, prostacyclins, anticancer drugs, antimetabolitic drugs, miotics, cholinergics, adrenergic antagonists, anticonvulsants, antianxiety agents, major tranquilizers, antidepressants, anesthetics, analgesics, anabolic steroids, estrogens,